Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of beta thalassemia (BT) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of BT for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s BT forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of BT?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BT over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 30 BT patient populations, as follows:

  • Diagnosed BT prevalent cases.
  • Diagnosed BT major prevalent cases.
  • Diagnosed BT intermedia prevalent cases.
  • Diagnosed B0/B0 BT major prevalent cases.
  • Diagnosed B0/B+ BT major prevalent cases.
  • Diagnosed B+/B+ BT major prevalent cases.
  • Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – younger than 12 years old.
  • Diagnosed B0/B0 BT major prevalent cases with matched related HSC transplantation – 12 years of age or older.
  • Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – younger than 12 years old.
  • Diagnosed B0/B0 BT prevalent cases without matched related HSC transplantation – 12 years of age or older.
  • Diagnosed BT intermedia prevalent cases requiring transfusions.
  • Diagnosed BT major pediatric prevalent cases.
  • Diagnosed BT major adult prevalent cases.
  • … and many more (details available on request).

Note: coverage may vary by country.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…